Eisai Clinical Trials

An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment

E7080-G000-205 Ph1b

Study Overview

E7080
lenvatinib
NCT01136733, EU CTR 2010-019484-10
Aug 2010 - Jun 2014
Renal Cell Carcinoma
Determine the DLTs, MTD and establish the recommended dose for Phase 2

  • Males and females (age 18 and over)

  • Completed

  • Phase 1b

  • United Kingdom, United States See more

Results

CSR Synopsis

Download PDF

Lay Summary

Download PDF
Publication reference citation

Molina M et al. A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Cancer Chemother Pharmacol 2014 Jan; 73 (1):181-9. DOI: 10.1007/s00280-013-2339-y

Data Sharing

ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.

Redacted documents are available upon request for this study.

Document type Availability
Protocol
SAP
Sample CRF
Full CSR